Compare Albemarle Corp. (ALB) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Albemarle Corp. vs UnitedHealth Group Inc — how do they compare? Albemarle Corp. trades at $128.09 (market cap $15.22B), while UnitedHealth Group Inc trades at $428.58 (market cap $388.86B). The key difference: UnitedHealth Group Inc is far larger — about 25.5× Albemarle Corp.'s market cap, and UnitedHealth Group Inc pays the higher dividend (2.17%). Which is the better fit depends on your goals.
| ALB | UNH | |
|---|---|---|
Market Cap | $15.22B | $388.86B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $428.19 |
52-Week Low | $67.30 | $237.77 |
Enterprise Value | $18.24B | $435.55B |
Dividend Yield | 1.26% | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) is trading at $129.02, down 4.82% over the past 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a low P/E of 5.12 and negative net income margin of -4.24% for 2025, though Q1 2026 earnings beat expectations. Recent news highlights a focus on debt reduction and energy storage system demand as lithium prices rebound. Cash flow improved in 2025 with net cash flow of $425.77 million, while the balance sheet reflects a debt-to-asset ratio of 19.8%.
The outlook for ALB hinges on lithium price recovery and execution in energy storage markets. Analyst consensus is mixed with a $227.10 price target suggesting significant upside, but risks include volatile lithium markets and ongoing profitability challenges. The stock's current level near key support at $128 may attract value investors, though macroeconomic and commodity pressures remain headwinds.
UnitedHealth Group (UNH) trades at $417.99, down 1.73% today, but maintains a bullish technical signal with strong moving averages and support near $414. Revenue grew to $447.57B in 2025, though net income margin compressed to 2.68%. Recent news highlights strategic moves to reduce pediatric prior authorizations and ongoing shareholder returns via dividends and buybacks.
Outlook remains positive with analyst consensus at Buy (82.69%) and a $419.47 price target, though regulatory risks from lawsuits and margin pressures pose challenges. The stock's valuation at a P/E of 31.48 appears rich relative to historical norms, requiring sustained earnings growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
